BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 21924649)

  • 21. Correlation of pathological grade and tumor stage of urothelial carcinomas with CD109 expression.
    Hagikura M; Murakumo Y; Hasegawa M; Jijiwa M; Hagiwara S; Mii S; Hagikura S; Matsukawa Y; Yoshino Y; Hattori R; Wakai K; Nakamura S; Gotoh M; Takahashi M
    Pathol Int; 2010 Nov; 60(11):735-43. PubMed ID: 20946523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Behavior of urothelial carcinoma with respect to anatomical location.
    Catto JW; Yates DR; Rehman I; Azzouzi AR; Patterson J; Sibony M; Cussenot O; Hamdy FC
    J Urol; 2007 May; 177(5):1715-20. PubMed ID: 17437794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder.
    Miyamoto H; Yao JL; Chaux A; Zheng Y; Hsu I; Izumi K; Chang C; Messing EM; Netto GJ; Yeh S
    BJU Int; 2012 Jun; 109(11):1716-26. PubMed ID: 22221549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pseudoangiosarcomatous urothelial carcinoma of the urinary bladder.
    Paner GP; Cox RM; Richards K; Akki A; Gokden N; Lopez-Beltran A; Krausz T; McKenney JK; Steinberg GD
    Am J Surg Pathol; 2014 Sep; 38(9):1251-9. PubMed ID: 25133708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of tumor-associated trypsin inhibitor (TATI) expression with molecular markers, pathologic features and clinical outcomes of urothelial carcinoma of the urinary bladder.
    Patschan O; Shariat SF; Chade DC; Karakiewicz PI; Ashfaq R; Lotan Y; Hotakainen K; Stenman UH; Bjartell A
    World J Urol; 2012 Dec; 30(6):785-94. PubMed ID: 21739120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?
    Garczyk S; Schneider U; Lurje I; Becker K; Vögeli TA; Gaisa NT; Knüchel R
    PLoS One; 2018; 13(8):e0202965. PubMed ID: 30138427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A-FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells.
    Boiteux G; Lascombe I; Roche E; Plissonnier ML; Clairotte A; Bittard H; Fauconnet S
    Int J Cancer; 2009 Apr; 124(8):1820-8. PubMed ID: 19115207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urothelial carcinoma of the bladder, lipid cell variant: clinicopathologic findings and LOH analysis.
    Lopez-Beltran A; Amin MB; Oliveira PS; Montironi R; Algaba F; McKenney JK; de Torres I; Mazerolles C; Wang M; Cheng L
    Am J Surg Pathol; 2010 Mar; 34(3):371-6. PubMed ID: 20139762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. E-cadherin expression in invasive urothelial carcinoma.
    Sun W; Herrera GA
    Ann Diagn Pathol; 2004 Feb; 8(1):17-22. PubMed ID: 15129905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New insights into the influence of cigarette smoking on urothelial carcinogenesis: smoking-induced gene expression in tumor-free urothelium might discriminate muscle-invasive from nonmuscle-invasive urothelial bladder cancer.
    Gabriel U; Li L; Bolenz C; Steidler A; Kränzlin B; Saile M; Gretz N; Trojan L; Michel MS
    Mol Carcinog; 2012 Nov; 51(11):907-15. PubMed ID: 21976419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification.
    Santos L; Amaro T; Costa C; Pereira S; Bento MJ; Lopes P; Oliveira J; Criado B; Lopes C
    Int J Cancer; 2003 Jun; 105(2):267-72. PubMed ID: 12673690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Grainyhead-Like 3 Influences Migration and Invasion of Urothelial Carcinoma Cells.
    Wezel F; Lustig J; Azoitei A; Liu J; Meessen S; Najjar G; Zehe V; Faustmann P; Zengerling F; John A; Martini T; Bolenz C; Günes C
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33803949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator.
    Inoue S; Mizushima T; Fujita K; Meliti A; Ide H; Yamaguchi S; Fushimi H; Netto GJ; Nonomura N; Miyamoto H
    Hum Pathol; 2017 Jun; 64():83-90. PubMed ID: 28428106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicting tumor outcomes in urothelial bladder carcinoma: turning pathways into clinical biomarkers of prognosis.
    Ehdaie B; Theodorescu D
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1103-10. PubMed ID: 18588455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder.
    Koga F; Kawakami S; Fujii Y; Saito K; Ohtsuka Y; Iwai A; Ando N; Takizawa T; Kageyama Y; Kihara K
    Clin Cancer Res; 2003 Nov; 9(15):5501-7. PubMed ID: 14654529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urothelial neoplasms of the urinary bladder occurring in young adult and pediatric patients: a comprehensive review of literature with implications for patient management.
    Paner GP; Zehnder P; Amin AM; Husain AN; Desai MM
    Adv Anat Pathol; 2011 Jan; 18(1):79-89. PubMed ID: 21169741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histologic grading of urothelial carcinoma: a reappraisal.
    Cheng L; MacLennan GT; Lopez-Beltran A
    Hum Pathol; 2012 Dec; 43(12):2097-108. PubMed ID: 22542126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD10 and E-cad expression in urinary bladder urothelial and squamous cell carcinoma.
    Omran OM
    J Environ Pathol Toxicol Oncol; 2012; 31(3):203-12. PubMed ID: 23339695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Correlation of genetic and cytogenetic alterations in pathological aggressiveness urothelial carcinoma of the bladder: Performance of BCA-1, a mini-array comparative genomic hybridisation-based test].
    Léon P; Cancel Tassin G; Sighar K; Compérat E; Gaffory C; Ondet V; Hugonin S; Audouin M; Doizi S; Traxer O; Ciofu C; Rouprêt M; Lacave R; Cussenot O
    Prog Urol; 2017; 27(8-9):451-457. PubMed ID: 28576425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urachal carcinomas of the nonglandular type: salient features and considerations in pathologic diagnosis.
    Paner GP; Barkan GA; Mehta V; Sirintrapun SJ; Tsuzuki T; Sebo TJ; Jimenez RE
    Am J Surg Pathol; 2012 Mar; 36(3):432-42. PubMed ID: 22301493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.